UDD Logo
CRIS - Current Research Information System
New user? Click here to register.Have you forgotten your password?
Communities & Collections
Research Outputs
Fundings & Projects
Researchers
Datasets
Statistics
  1. Home
  2. CRIS
  3. Publications
  4. IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models
Details

IGF2 prevents dopaminergic neuronal loss and decreases intracellular alpha-synuclein accumulation in Parkinson’s disease models

Journal
Cell Death Discovery
ISSN
2058-7716
Date Issued
2023
Author(s)
Javiera Arcos
Felipe Grunenwald
Denisse Sepulveda
Carolina Jerez
Valentina Urbina
Tomas Huerta
Paulina Troncoso-escudero
Facultad de Medicina Clínica Alemana Universidad del Desarrollo  
Daniel Tirado
Angela Perez
Rodrigo Diaz-Espinoza
Esteban Nova
Ulrich Kubitscheck
Juan Eduardo Rodriguez-Gatica
Claudio Hetz
Jorge Toledo
Pablo Ahumada
Diego Rojas-Rivera
Elisa Martín-Montañez
María Garcia-Fernandez
René L. Vidal
Type
Resource Types::text::journal::journal article
Scopus ID
2-s2.0-85178413601
WoS ID
WOS:001112295200001
DOI
10.1038/s41420-023-01734-1
URL
https://investigadores.udd.cl/handle/123456789/8427
URL Institutional Repository
https://hdl.handle.net/11447/8906
Abstract
<jats:title>Abstract</jats:title><jats:p>Parkinson’s disease (PD) is the second most common late-onset neurodegenerative disease and the predominant cause of movement problems. PD is characterized by motor control impairment by extensive loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc). This selective dopaminergic neuronal loss is in part triggered by intracellular protein inclusions called Lewy bodies, which are composed mainly of misfolded alpha-synuclein (α-syn) protein. We previously reported insulin-like growth factor 2 (IGF2) as a key protein downregulated in PD patients. Here we demonstrated that IGF2 treatment or IGF2 overexpression reduced the α-syn aggregates and their toxicity by IGF2 receptor (IGF2R) activation in cellular PD models. Also, we observed IGF2 and its interaction with IGF2R enhance the α-syn secretion. To determine the possible IGF2 neuroprotective effect in vivo we used a gene therapy approach in an idiopathic PD model based on α-syn preformed fibrils intracerebral injection. IGF2 gene therapy revealed a significantly preventing of motor impairment in idiopathic PD model. Moreover, IGF2 expression prevents dopaminergic neuronal loss in the SN together with a decrease in α-syn accumulation (phospho-α-syn levels) in the striatum and SN brain region. Furthermore, the IGF2 neuroprotective effect was associated with the prevention of synaptic spines loss in dopaminergic neurons in vivo. The possible mechanism of IGF2 in cell survival effect could be associated with the decrease of the intracellular accumulation of α-syn and the improvement of dopaminergic synaptic function. Our results identify to IGF2 as a relevant factor for the prevention of α-syn toxicity in both in vitro and preclinical PD models.</jats:p>
Logo Universidad de Desarrollo
Encuéntranos en:

Sede Santiago

Av. Plaza 680, Las Condes

Contacto|Mapa

Sede Concepción

Ainavillo 456, Concepción

Contacto|Mapa

Hosting & SupportLogo Scimago Lab

Built with DSpace-CRIS software - Extension maintained and optimized by 4science

  • Accessibility settings
  • Privacy policy
  • End User Agreement
  • Send Feedback
Repository logo COAR Notify